- Rein Therapeutics (RNTX, Financial) collaborates with Qureight Ltd to incorporate deep-learning technology in its Phase 2 trial of LTI-03.
- Phase 1b trials of LTI-03 showed promising results with positive trends in seven out of eight biomarkers.
- Qureight's AI platform will enhance the analysis of lung imaging data to improve trial efficiency and insights.
Rein Therapeutics (RNTX), a biopharmaceutical company, has announced a strategic collaboration with Qureight Ltd to integrate deep-learning technology into its forthcoming Phase 2 trial for LTI-03, a treatment aimed at idiopathic pulmonary fibrosis (IPF). This partnership is designed to leverage Qureight's expertise in imaging analytics to deepen the understanding of LTI-03's impact on lung structure and function.
The integration follows positive Phase 1b trial results, where LTI-03 demonstrated encouraging outcomes across multiple biomarkers. Of the eight biomarkers assessed, seven showed positive trends, with five exhibiting dose-dependent effects and four reaching statistical significance. These results provide a scientific rationale for progressing to Phase 2 trials.
Qureight will provide comprehensive imaging core lab services, including AI-powered analysis of lung imaging data. Their advanced technology will measure changes in fibrotic, vascular, and airway compartments, aiming to uncover correlations between these volumetric changes and biomarker activity. This approach promises to deliver more granular insights into LTI-03's therapeutic potential and may enhance the trial's efficiency by reducing image interpretation time.
LTI-03, a novel Caveolin-1-related peptide, targets multiple pathways in lung cells, offering a dual mechanism to both modulate pro-fibrotic activity and protect alveolar epithelial cells. The Phase 2 trial will focus on LTI-03's safety, tolerability, and activity across biomarkers, as well as its ability to support healthy tissue regeneration.
This collaboration represents a significant step in advancing treatment options for IPF, a chronic lung disease with limited available therapies. By integrating cutting-edge AI technology, Rein Therapeutics aims to accelerate the trial process and gain deeper insights into the potential benefits of LTI-03 for patients with IPF.
